Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Jennison Associates LLC

Jennison Associates LLC grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 82.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 813,861 shares of the company's stock after purchasing an additional 366,763 shares during the period. Jennison Associates LLC owned about 1.29% of Vera Therapeutics worth $34,418,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. First Turn Management LLC increased its stake in Vera Therapeutics by 53.3% during the third quarter. First Turn Management LLC now owns 326,494 shares of the company's stock worth $14,431,000 after purchasing an additional 113,550 shares during the period. SG Americas Securities LLC increased its stake in Vera Therapeutics by 116.7% during the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after purchasing an additional 10,916 shares during the period. Lord Abbett & CO. LLC increased its stake in Vera Therapeutics by 41.1% during the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock worth $18,830,000 after purchasing an additional 124,197 shares during the period. Barclays PLC increased its stake in Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company's stock worth $3,774,000 after purchasing an additional 41,394 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Vera Therapeutics by 3.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company's stock worth $15,992,000 after purchasing an additional 10,717 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wolfe Research assumed coverage on shares of Vera Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $49.00 target price on the stock. JPMorgan Chase & Co. upped their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Wedbush upped their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price on the stock. Finally, Scotiabank started coverage on shares of Vera Therapeutics in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $60.00 target price on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $65.44.

Vera Therapeutics Stock Performance

Shares of VERA stock traded down $1.04 during trading hours on Friday, hitting $36.14. The stock had a trading volume of 451,048 shares, compared to its average volume of 750,517. The firm has a market capitalization of $2.29 billion, a PE ratio of -13.85 and a beta of 1.11. Vera Therapeutics, Inc. has a twelve month low of $31.77 and a twelve month high of $51.61. The stock's 50 day moving average is $40.49 and its 200 day moving average is $40.98. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Transactions at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 17,500 shares of the company's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the sale, the chief executive officer now owns 85,942 shares in the company, valued at $3,701,521.94. This represents a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 52,500 shares of company stock worth $2,305,625 over the last 90 days. 21.70% of the stock is currently owned by insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.